BridgeMD
New treatment option for Smoking Behaviors
Official title Nordic Spirit Pouch Nicotine Pharmacokinetics Abuse Liability
ClinicalTrials.gov ID: NCT07476144
What this study is testing
What is Participants will place the pouch between their top lip and their gum for 30 minutes as per use instructions.?
Participants will place the pouch between their top lip and their gum for 30 minutes as per use instructions. is an investigational medicine, being studied as a potential treatment for smoking behaviors.
Also referred to as Nicotine Pouch.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Nicotine pharmacokinetics and subjective effects of 9 Nordic Spirit Nicotine Pouch Products in adult cigarette smokers: A controlled, randomized, cross-over study with a balanced incomplete block design.
- Phase 1: an early, usually small safety study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 22 to 65. Healthy volunteers may be eligible.
You may be able to join if
- Voluntary consent to participate in this study documented on the signed ICF.
- Healthy adult males and females ≥22 and ≤65 years of age, at screening.
- Smokers and smokers that use other tobacco products (i.e., snus, moist snuff, Electronic Nicotine Delivery Systems, NP) will be considered. Smoking...
- Participants must demonstrate the ability to use a 12-mg NP for 30 minutes.
- Participants who use THC, must be willing to abstain from THC use for 7 days before Check-in and able to participate in the study without THC use.
You likely can't join if
- Self-reported puffers (i.e., adult smokers who draw smoke from the cigarette into the mouth and throat but do not inhale).
- Any postponement of a quit attempt to participate in the study; or any attempts to quit smoking in the 3 months prior to Check-in).
- Poor dentition that prevents participant from using nicotine gum.
- History or presence of any type of malignant tumor or clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine...
- Current evidence or any history of congestive heart failure.
- Any other condition or prior therapy that, in the Investigator's opinion, would make the participant unsuitable for the study, or unable or unwilling...
See the full eligibility criteria
Who can join
- Voluntary consent to participate in this study documented on the signed ICF.
- Healthy adult males and females ≥22 and ≤65 years of age, at screening.
- Smokers and smokers that use other tobacco products (i.e., snus, moist snuff, Electronic Nicotine Delivery Systems, NP) will be considered. Smoking history (self-reported at screening) of an average of at least 5 but no...
- Participants must demonstrate the ability to use a 12-mg NP for 30 minutes.
- Participants who use THC, must be willing to abstain from THC use for 7 days before Check-in and able to participate in the study without THC use.
- Participants must be generally healthy, free of lifetime malignant tumors, and without clinically significant abnormalities as assessed by the Investigator based on the review of medical and surgical history, physical...
- Screening and first Check-in blood pressure ≤150/90 mmHg measured after being in the supine position or in the most recumbent position possible for at least 5 minutes. Two rechecks may be performed at the Principal...
- Positive urine cotinine (≥200 ng/mL) at screening.
- Exhaled carbon monoxide ≥8 ppm at screening.
- Male participants, if not surgically sterilized, must agree to use adequate contraception and not donate sperm from first Check-in (Day -1) to the clinical site until 90 days after the last administration of study...
- Negative pregnancy test at screening and first Check-in (Day -1) for all female participants.
- Female participants who are heterosexually active and of childbearing potential (e.g., neither surgically sterile at least 6 months prior to first Check-in nor postmenopausal with amenorrhea for at least 12 months prior...
- Hormonal (e.g., oral, vaginal ring, transdermal patch, implant, injection) consistently for at least 3 months prior to first Check-in, when used in combination with male condoms with spermicide (use of NuvaRing is at...
- Double barrier (e.g., condom with spermicide or diaphragm with spermicide) consistently for at least 2 weeks prior to first Check-in
- Intrauterine device or system (utilize Principal Investigator discretion regarding use of hormonal or nonhormonal devices) for at least 3 months prior to first Check-in
- Exclusive partner who is clinically sterile (i.e., documented infertility or surgical sterilization; see below for additional information on sterility) or has been vasectomized for at least 6 months (inclusive) prior to...
- Note: Sexual abstinence, defined as refraining from intercourse, is allowed when this is in line with the preferred and usual lifestyle of the participant. Female participants of childbearing potential who are not...
- Female participants who are of nonchildbearing potential must have undergone one of the following sterilization procedures at least 6 months prior to first Check-in:
- Hysteroscopic sterilization (including Essure or similar nonsurgical sterilization procedures)
- Bilateral tubal ligation or bilateral salpingectomy
- Hysterectomy
- Bilateral oophorectomy
- Or be postmenopausal with amenorrhea for at least 12 months prior to first Check-in and have FSH levels consistent with postmenopausal status.
- Able to communicate effectively with the study personnel and willing to comply with the requirements of the study.
- Willing and able to use all of the study products in-confinement and product use sessions
What rules you out
- Self-reported puffers (i.e., adult smokers who draw smoke from the cigarette into the mouth and throat but do not inhale).
- Any postponement of a quit attempt to participate in the study; or any attempts to quit smoking in the 3 months prior to Check-in).
- Poor dentition that prevents participant from using nicotine gum.
- History or presence of any type of malignant tumor or clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, pulmonary, immunologic, psychiatric, or...
- Current evidence or any history of congestive heart failure.
- Any other condition or prior therapy that, in the Investigator's opinion, would make the participant unsuitable for the study, or unable or unwilling to comply with the study procedures.
- All prescribed medication must have been stopped at least 14 days prior to (first) admission to the clinical site. An exception is made for hormonal contraceptives that may be used throughout the study.
- All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (eg, St. John's wort) must have been stopped at least 14 days prior to (first) admission to the clinical site. An...
- Clinically significant abnormal vital sign, physical examination (including oral cavity and oropharynx), medical history, or clinical laboratory finding(s), in the opinion of the Investigator.
- Positive test for HIV-1 or HIV-2; or HBsAg or HCV consistent with current infection at screening.
- Diabetes mellitus that is not controlled by diet/exercise alone, in the opinion of the Investigator. Fasting plasma glucose \>126 mg/dL (7 mmol/L) is exclusionary. One recheck may be performed for fasting plasma glucose...
- An acute illness (e.g., upper respiratory infection, viral infection) requiring treatment with prescribed medicines within 2 weeks prior to Check-in.
- History of surgery or major trauma within 12 weeks of screening, or surgery planned during the study through EOS.
- History of alcohol abuse or drug abuse within 24 months prior to Check-in.
- Consumption of alcohol-containing food or beverages within 48 hours prior to Check-in.
- Positive screen for alcohol (breath or urine) or drugs of abuse (urine), regardless of the reason of use at screening or Check-in, with the exception of positive results for THC. If positive for THC at check-in (Day...
- Fever (i.e., body temperature \>100.5°F) at screening or Check-in; 1 recheck may be performed at the Investigator's discretion.
- BMI \ 40.0 kg/m2 at screening.
- Estimated glomerular filtration rate \<80 mL/minute using the CKD-EPI formula (Medscape) at screening.
- Serum alanine aminotransferase ≥1.5 times the upper limit of normal and/or aspartate aminotransferase ≥2.0 times the upper limit of normal at screening; 1 recheck may be performed at the Investigator's discretion.
- Female participants who are pregnant (positive pregnancy test at screening or Check-in), lactating, or intend to become pregnant from screening through EOS.
- Use of prescription or OTC bronchodilator medication (e.g., inhaled or oral β-agonists) for treatment of any illness within 12 months prior to Check-in.
- Use of antibiotics within 2 weeks prior to Check-in.
- Use of medications known or suspected to interact with cytochrome P450 2A6 (including, but not limited to, amiodarone, amlodipine, amobarbital, buprenorphine, clofibrate, clotrimazole, desipramine, disulfiram...
- Has taken other investigational drugs/products or participated in any clinical study for an investigational drug, device, biologic, or for a tobacco product within 30 days or 5 half-lives (if known) of the...
- Has received a vaccination within 14 days prior to Check-in.
- Plasma donation within 7 days prior to Day 1.
- Donation of ≥1 unit of blood or blood products (with the exception of plasma as noted), had significant blood loss \>450 mL, or received whole blood or a blood product transfusion within 56 days prior to Check-in.
- Strenuous activity (as assessed by the Investigator) within 48 hours prior to Check-in.
- Participant or a first-degree relative (i.e., parent, sibling, child, spouse) is a current or former employee of the tobacco industry, or a named party or class representative in litigation with any tobacco company.
- Participant or a first-degree relative (i.e., parent, sibling, child, spouse) is a current employee of the study site or service provider.
- Unwilling or unlikely to comply with the requirements of the study
The study team makes the final eligibility decision.
Where it's taking place
- Knoxville, Tennessee, United States
- San Antonio, Texas, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 22 years to 65 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Knoxville, Tennessee, United States; San Antonio, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.